BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 38097911)

  • 21. Glycoengineering of Natural Killer Cells with CD22 Ligands for Enhanced Anticancer Immunotherapy.
    Wang X; Lang S; Tian Y; Zhang J; Yan X; Fang Z; Weng J; Lu N; Wu X; Li T; Cao H; Li Z; Huang X
    ACS Cent Sci; 2020 Mar; 6(3):382-389. PubMed ID: 32232138
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Poly(ethylene glycol)-block-poly(ε-caprolactone)-and phospholipid-based stealth nanoparticles with enhanced therapeutic efficacy on murine breast cancer by improved intracellular drug delivery.
    He X; Li L; Su H; Zhou D; Song H; Wang L; Jiang X
    Int J Nanomedicine; 2015; 10():1791-804. PubMed ID: 25784805
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Engineered Three-Dimensional Tumor Models to Study Natural Killer Cell Suppression.
    Temples MN; Adjei IM; Nimocks PM; Djeu J; Sharma B
    ACS Biomater Sci Eng; 2020 Jul; 6(7):4179-4199. PubMed ID: 33463353
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A three-dimensional hyaluronic acid-based niche enhances the therapeutic efficacy of human natural killer cell-based cancer immunotherapy.
    Ahn YH; Ren L; Kim SM; Seo SH; Jung CR; Kim DS; Noh JY; Lee SY; Lee H; Cho MY; Jung H; Yoon SR; Kim JE; Lee SN; Kim S; Shin IW; Shin HS; Hong KS; Lim YT; Choi I; Kim TD
    Biomaterials; 2020 Jul; 247():119960. PubMed ID: 32278822
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hyaluronic acid-serum albumin conjugate-based nanoparticles for targeted cancer therapy.
    Edelman R; Assaraf YG; Levitzky I; Shahar T; Livney YD
    Oncotarget; 2017 Apr; 8(15):24337-24353. PubMed ID: 28212584
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hyaluronic acid-nimesulide conjugates as anticancer drugs against CD44-overexpressing HT-29 colorectal cancer in vitro and in vivo.
    Jian YS; Chen CW; Lin CA; Yu HP; Lin HY; Liao MY; Wu SH; Lin YF; Lai PS
    Int J Nanomedicine; 2017; 12():2315-2333. PubMed ID: 28392690
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Small interfering RNA for cancer treatment: overcoming hurdles in delivery.
    Charbe NB; Amnerkar ND; Ramesh B; Tambuwala MM; Bakshi HA; Aljabali AAA; Khadse SC; Satheeshkumar R; Satija S; Metha M; Chellappan DK; Shrivastava G; Gupta G; Negi P; Dua K; Zacconi FC
    Acta Pharm Sin B; 2020 Nov; 10(11):2075-2109. PubMed ID: 33304780
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tumor-associated hyaluronan limits efficacy of monoclonal antibody therapy.
    Singha NC; Nekoroski T; Zhao C; Symons R; Jiang P; Frost GI; Huang Z; Shepard HM
    Mol Cancer Ther; 2015 Feb; 14(2):523-32. PubMed ID: 25512619
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hyaluronic Acid-Coated Camptothecin Nanocrystals for Targeted Drug Delivery to Enhance Anticancer Efficacy.
    Wang J; Muhammad N; Li T; Wang H; Liu Y; Liu B; Zhan H
    Mol Pharm; 2020 Jul; 17(7):2411-2425. PubMed ID: 32437163
    [TBL] [Abstract][Full Text] [Related]  

  • 30. One-pot preparation of hyaluronic acid-coated iron oxide nanoparticles for magnetic hyperthermia therapy and targeting CD44-overexpressing cancer cells.
    Soleymani M; Velashjerdi M; Shaterabadi Z; Barati A
    Carbohydr Polym; 2020 Jun; 237():116130. PubMed ID: 32241421
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hyaluronic acid-capped compact silica-supported mesoporous titania nanoparticles for ligand-directed delivery of doxorubicin.
    Gupta B; Poudel BK; Ruttala HB; Regmi S; Pathak S; Gautam M; Jin SG; Jeong JH; Choi HG; Ku SK; Yong CS; Kim JO
    Acta Biomater; 2018 Oct; 80():364-377. PubMed ID: 30201431
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Poly(ethylene glycol)-modification of the phospholipid vesicles by using the spontaneous incorporation of poly(ethylene glycol)-lipid into the vesicles.
    Sou K; Endo T; Takeoka S; Tsuchida E
    Bioconjug Chem; 2000; 11(3):372-9. PubMed ID: 10821653
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Enhanced drug loading on magnetic nanoparticles by layer-by-layer assembly using drug conjugates: blood compatibility evaluation and targeted drug delivery in cancer cells.
    Manju S; Sreenivasan K
    Langmuir; 2011 Dec; 27(23):14489-96. PubMed ID: 21988497
    [TBL] [Abstract][Full Text] [Related]  

  • 34.
    Mac Donald A; Guipouy D; Lemieux W; Harvey M; Bordeleau LJ; Guay D; Roméro H; Li Y; Dion R; Béland K; Haddad E
    Front Immunol; 2023; 14():1231916. PubMed ID: 37675109
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PEGylated hyaluronic acid-coated liposome for enhanced in vivo efficacy of sorafenib via active tumor cell targeting and prolonged systemic exposure.
    Mo L; Song JG; Lee H; Zhao M; Kim HY; Lee YJ; Ko HW; Han HK
    Nanomedicine; 2018 Feb; 14(2):557-567. PubMed ID: 29248675
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bispecific antibody-mediated redirection of NKG2D-CAR natural killer cells facilitates dual targeting and enhances antitumor activity.
    Zhang C; Röder J; Scherer A; Bodden M; Pfeifer Serrahima J; Bhatti A; Waldmann A; Müller N; Oberoi P; Wels WS
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599028
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hyaluronic acid-coated liposomes for active targeting of gemcitabine.
    Arpicco S; Lerda C; Dalla Pozza E; Costanzo C; Tsapis N; Stella B; Donadelli M; Dando I; Fattal E; Cattel L; Palmieri M
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):373-80. PubMed ID: 23791684
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Real-Time Tracking of
    Uong TNT; Lee KH; Ahn SJ; Kim KW; Min JJ; Hyun H; Yoon MS
    Front Immunol; 2018; 9():825. PubMed ID: 29770131
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Preparation of target antigens specifically recognized by human natural killer cells.
    Henkart PA; Lewis JT; Ortaldo JR
    Nat Immun Cell Growth Regul; 1986; 5(3):113-26. PubMed ID: 2426585
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hyaluronic-Acid-Tagged Cubosomes Deliver Cytotoxics Specifically to CD44-Positive Cancer Cells.
    Pramanik A; Xu Z; Ingram N; Coletta PL; Millner PA; Tyler AII; Hughes TA
    Mol Pharm; 2022 Dec; 19(12):4601-4611. PubMed ID: 35938983
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.